Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-1 plus Doxorubicin in Advanced Sarcoma
NCT03002805Phase 1Unknown
- Sponsor
- CBA Pharma, Inc.
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tetrandrine in sarcoma, sponsored by CBA Pharma, Inc. Primary endpoint: Maximum Tolerated Dose at 3 years. Status: unknown.
02
Drugs
tetrandrine
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT03002805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002805.